The roles of EZH2 in cancer and its inhibitors

被引：79

作者：

Liu, Yuankai ^{[1
]}

Yang, Qiong ^{[1
]}

机构：

[1] Beijing Normal Univ, Beijing Key Lab Gene Resource & Mol Dev, Beijing, Peoples R China

来源：

MEDICAL ONCOLOGY | 2023年 / 40卷 / 06期

关键词：

EZH2; PRC2; Histone methylation; Cancer treatment; Signal pathways; EPITHELIAL-MESENCHYMAL TRANSITION; HISTONE METHYLTRANSFERASE EZH2; BLOCKS H3K27 METHYLATION; SMALL-MOLECULE INHIBITOR; GROUP PROTEIN EZH2; CELL LUNG-CANCER; STEM-LIKE CELLS; SELECTIVE-INHIBITION; ANTITUMOR EFFICACY; TUMOR-SUPPRESSOR;

D O I：

10.1007/s12032-023-02025-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The enhancer of zeste homolog 2 (EZH2) is encoded by the Enhancer of zeste 2 polycomb repressive complex 2 subunit gene. EZH2 is involved in the cell cycle, DNA damage repair, cell differentiation, autophagy, apoptosis, and immunological modulation. The main function of EZH2 is to catalyze the methylation of H3 histone of H3K27Me3, which inhibits the transcription of target genes, such as tumor suppressor genes. EZH2 also forms complexes with transcriptions factors or directly binds to the promoters of target genes, leading to regulate gene transcriptions. EZH2 has been as a prominent target for cancer therapy and a growing number of potential targeting medicines have been developed. This review summarized the mechanisms that EZH2 regulates gene transcription and the interactions between EZH2 and important intracellular signaling molecules (Wnt, Notch, MEK, Akt) and as well the clinical applications of EZH2-targeted drugs.

引用

页数：29

共 114 条

[1] TNF Inhibits Notch-1 in Skeletal Muscle Cells by Ezh2 and DNA Methylation Mediated Repression: Implications in Duchenne Muscular Dystrophy [J].

Acharyya, Swarnali ;

Sharma, Sudarshana M. ;

Cheng, Alfred S. ;

Ladner, Katherine J. ;

He, Wei ;

Kline, William ;

Wang, Huating ;

Ostrowski, Michael C. ;

Huang, Tim H. ;

Guttridge, Denis C. .

PLOS ONE, 2010, 5 (08)

[2] Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2 [J].

Barnash, Kimberly D. ;

The, Juliana ;

Norris-Drouin, Jacqueline L. ;

Cholensky, Stephanie H. ;

Worley, Beau M. ;

Li, Fengling ;

Stuckey, Jacob I. ;

Brown, Peter J. ;

Vedadi, Masoud ;

Arrowsmith, Cheryl H. ;

Frye, Stephen V. ;

James, Lindsey I. .

ACS COMBINATORIAL SCIENCE, 2017, 19 (03) :161-172

[3] EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation [J].

Beguelin, Wendy ;

Popovic, Relja ;

Teater, Matt ;

Jiang, Yanwen ;

Bunting, Karen L. ;

Rosen, Monica ;

Shen, Hao ;

Yang, Shao Ning ;

Wang, Ling ;

Ezponda, Teresa ;

Martinez-Garcia, Eva ;

Zhang, Haikuo ;

Zheng, Yupeng ;

Verma, Sharad K. ;

McCabe, Michael T. ;

Ott, Heidi M. ;

Van Aller, Glenn S. ;

Kruger, Ryan G. ;

Liu, Yan ;

McHugh, Charles F. ;

Scott, David W. ;

Chung, Young Rock ;

Kelleher, Neil ;

Shaknovich, Rita ;

Creasy, Caretha L. ;

Gascoyne, Randy D. ;

Wong, Kwok-Kin ;

Cerchietti, Leandro ;

Levine, Ross L. ;

Abdel-Wahab, Omar ;

Licht, Jonathan D. ;

Elemento, Olivier ;

Melnick, Ari M. .

CANCER CELL, 2013, 23 (05) :677-692

[4] Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas [J].

Bisserier, Malik ;

Wajapeyee, Narendra .

BLOOD, 2018, 131 (19) :2125-2137

[5] Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis [J].

Boettcher, Martin ;

Bruns, Heiko ;

Voelkl, Simon ;

Lu, Junyan ;

Chartomatsidou, Elisavet ;

Papakonstantinou, Nikos ;

Mentz, Kristin ;

Buettner-Herold, Maike ;

Zenz, Thorsten ;

Herling, Marco ;

Huber, Wolfgang ;

Ghia, Paolo ;

Stamatopoulos, Kostas ;

Mackensen, Andreas ;

Mougiakakos, Dimitrios .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (04)

[6] EZH2 Inhibitor Efficacy in Non-Hodgkin's Lymphoma Does Not Require Suppression of H3K27 Monomethylation [J].

Bradley, William D. ;

Arora, Shilpi ;

Busby, Jennifer ;

Balasubramanian, Srividya ;

Gehling, Victor S. ;

Nasveschuk, Christopher G. ;

Vaswani, Rishi G. ;

Yuan, Chih-Chi ;

Hatton, Charlie ;

Zhao, Feng ;

Williamson, Kaylyn E. ;

Iyer, Priyadarshini ;

Mendez, Jacqui ;

Campbell, Robert ;

Cantone, Nico ;

Garapaty-Rao, Shivani ;

Audia, James E. ;

Cook, Andrew S. ;

Dakin, Les A. ;

Albrecht, Brian K. ;

Harmange, Jean-Christophe ;

Daniels, Danette L. ;

Cummings, Richard T. ;

Bryant, Barbara M. ;

Normant, Emmanuel ;

Trojer, Patrick .

CHEMISTRY & BIOLOGY, 2014, 21 (11) :1463-1475

[7] EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity [J].

Campbell, John E. ;

Kuntz, Kevin W. ;

Knutson, Sarah K. ;

Warholic, Natalie M. ;

Keilhack, Heike ;

Wigle, Tim J. ;

Raimondi, Alejandra ;

Klaus, Christine R. ;

Rioux, Nathalie ;

Yokoi, Akira ;

Kawano, Satoshi ;

Minoshima, Yukinori ;

Choi, Hyeong-Wook ;

Scott, Margaret Porter ;

Waters, Nigel J. ;

Smith, Jesse J. ;

Chesworth, Richard ;

Moyer, Mikel P. ;

Copeland, Robert A. .

ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (05) :491-495

[8] JNK and STAT3 signaling pathways converge on Akt-mediated phosphorylation of EZH2 in bronchial epithelial cells induced by arsenic [J].

Chen, Bailing ;

Liu, Jia ;

Chang, Qingshan ;

Beezhold, Kevin ;

Lu, Yongju ;

Chen, Fei .

CELL CYCLE, 2013, 12 (01) :112-121

[9] Long Non-Coding RNA SNHG1 Regulates the Wnt/β-Catenin and PI3K/AKT/mTOR Signaling Pathways via EZH2 to Affect the Proliferation, Apoptosis, and Autophagy of Prostate Cancer Cell [J].

Chen, Junyi ;

Wang, Fubo ;

Xu, Huan ;

Xu, Lingfan ;

Chen, Dong ;

Wang, Jialiang ;

Huang, Sihuai ;

Wen, Yiqun ;

Fang, Longmin .

FRONTIERS IN ONCOLOGY, 2020, 10

[10] Long Noncoding RNA NEAT1, Regulated by the EGFR Pathway, Contributes to Glioblastoma Progression Through the WNT/β-Catenin Pathway by Scaffolding EZH2 [J].

Chen, Qun ;

Cai, Jinquan ;

Wang, Qixue ;

Wang, Yunfei ;

Liu, Mingyang ;

Yang, Jingxuan ;

Zhou, Junhu ;

Kang, Chunsheng ;

Li, Min ;

Jiang, Chuanlu .

CLINICAL CANCER RESEARCH, 2018, 24 (03) :684-695

← 1 2 3 4 5 6 7 8 9 10 →